Columbus Ohio

02/23/2019 2nd IBDH Annual Columbus Conference

February 23

8:00 am


  • Start: February 23 2019, 8:00 am
  • End: February 23 2019, 3:30 pm
  • Cost: Free of Charge - Pharmacists will pay a certification fee.
  • Credits: 6 credits


  • Hilton Columbus Downtown - Le Meridien (proximity to the Hilton)
  • We recommend going online for best rates or call Brian Hatzkilson at 949-851-5151
  • Valet parking will be offered at the Hilton


Valet parking Included


Topics Speakers
Personalized Treatment of IBD Dr. Marla Dubinsky
Management of Proctosigmoiditis failing Mesalamine Dr. Raymond Cross
Surgical and Medical Management of the Failing Pouch Dr. Feza Remzi
Medical and Surgical Management of Perianal Crohn’s Disease Dr. Ghassan Wahbeh
Management of Severe Refractory Ulcerative Colitis Dr. Brian Feagan
Management of Mild Crohn’s Ileitis Dr. Anita Afzali
Treatment of the Pregnant IBD Patient with Active Disease Dr. Heather Frey
Choosing a Therapy from the Expanding Options Dr. Scott D. Lee

Venue : Hilton Columbus Downtown 401 N High St, Columbus, OH 43215

Learning Objectives

After completion of this activity, participants will be able to:

  • Assess the benefits and limitations of personalized medicine in the context of managing patients with IBD.
  • List factors that should be evaluated in the selection of therapy for patients with Crohn’s disease and how to align these with the patients’ treatment goals.
  • List predictors of suboptimal response to medical therapies and describe approaches for monitoring and predicting treatment response in patients with CD.
  • Identify the most promising molecules in late-stage clinical development, with an emphasis on immunological targets and pharmacological properties.
  • Identify clinical gaps/controversies and apply evidence-based medical management of mild-to-moderate ulcerative colitis to individualize patient care.
  • Incorporate evidence-based treatment strategies to optimize outcomes in patients with moderate-to-severe UC who are sub-optimally controlled and/or considered to be treatment failures.
  • Examine the current clinical practice of post-operative management of Crohn’s disease and apply best practice medical management treatment strategies.
  • Apply the most recent evidence regarding family planning and the reproductive safety of IBD medications when counseling patients with IBD who are considering conception or who are pregnant.




















This activity is jointly provided by UCI School of Medicine and IBD Horizons

This activity is supported by an educational grant from Prometheus Laboratories Inc., Abbvie Inc. and Takeda Pharmaceuticals U.S.A., Inc, Janssen Biotech

CME Supporters


Target Audience

The target audience are healthcare providers caring for IBD patients: adult and pediatric gastroenterologists, advanced registered nurse practitioners and physician assistants, medical staff, dietician, surgeons, and pharmacists.

Statement of Need/Program Overview

This activity is jointly provided by UCI School of Medicine and IBD Horizons.

The management of IBD is highly dynamic with extensive, cutting-edge information deriving from a wealth of ongoing scientific, clinical, and therapeutic research programs. The mission of IBD Horizons® is to provide healthcare providers the opportunity to enhance their clinical knowledge by providing the most up-to-date information regarding the management of IBD. Cutting edge topics delivered by respected educators/leaders in the IBD field, as well as opportunities for interaction between the presenters and participants have been designed into the educational program.



This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and IBD Horizons. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

The University of California, Irvine School of Medicine designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

American Academy of Nurse Practitioners (AANP)

American Academy of Nurse Practitioners accepts CME-accredited courses for their members as part of their requirements for recertification. (Recertification FAQ)

American Nurses Credentialing Center (ANCC)

The ANCC accepts formally approved CME accredited courses for its members to gain CEUs (ANCC).

Pharmacist Accreditation

Pharmacists may petition the board for CE credit by submitting a Pharmacists Petition for Continuing Education Credit from A Non-Recognized Providerform from and a fee of $40 per hour of coursework. When submitting the petition, a copy of the completion certificate, a copy of the course brochure or advertisement, and course outline is required.

This is a knowledge based activity.

About UCI School of Medicine

The mission of University of California, Irvine School of Medicine Office of Continuing Medical Education is to provide educational activities to physicians and other healthcare professionals that reinforce basic medical knowledge, impart updated information on clinical practice and healthcare delivery, introduce new ideas, skills and technology and disseminate pertinent research findings in order to improve the quality of healthcare that is delivered by the participants in our programs.

This is in concert with the educational mission of the UC Irvine School of Medicine which supports the continuum of medical education through programs in undergraduate, graduate and continuing medical education.

The Office of Continuing Medical Education works with the vice dean, Medical Education and the Continuing Medical Education Committee of the UC Irvine Faculty Senate in order to fulfill its mission and to ensure that all of its educational activities are in full compliance with the essential areas, elements and policies of the Accreditation Council for Continuing Medical Education (ACCME).

The University of California, Irvine School of Medicine is accredited by the ACCME, with commendation, through July 2023.

Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.

Disclosure Policy
The University of California, Irvine School of Medicine requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by UCI School of Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty and moderators of this conference will provide full disclosure information of any relevant financial relationships to the participants prior to the activity.

Name of Faculty or Presenter

Scott D. Lee
Anita Afzali
Ghassan Wahbeh
Brian Feagan

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Ellen P. Seaback, CHCP – Nothing to disclose
Paul Strunc – Nothing to disclose

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of California, Irvine School of Medicine and IBD Horizons do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.